GUIDANCE
For the third year in a row, Rockwell Medical's annual performance was directly in line with its annual guidance. In 2025, Rockwell Medical's achieved net sales, gross margin and Adjusted EBITDA as follows:
| 2025 Annual Guidance | 2025 Actual | |
| Net Sales | $65.0M to $70.0M | $69.3M |
| Gross Margin | 16% to 18% | 17% |
| Adjusted EBITDA | ($0.5)M to $0.5M | $0.4M |
In 2026, we are working to drive sustainable, profitable growth by adding new customers and renewing contracts with existing customers, improving price and product mix, further enhancing operational efficiencies, and selectively expanding our portfolio through disciplined partnership and business development.
The Company projects its 2026 annual guidance as follows:
| 2026 Annual Guidance | |
| Adjusted EBITDA | $1 million to $2 million |
| Operating Cash Flow | Positive |
Login to comment